^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Nasopharyngeal Carcinoma |
| Drug: | Yutuo (zimberelimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma
Published date:
03/07/2021
Excerpt:
40.9% patients (n = 79) were PD-L1 high-expression, especially in nasopharyngeal cancer (71.8%) and esophageal squamous cell cancer (48.3%) cohorts. Patients with PD-L1 high-expression responded significantly better than those with PD-L1 low-expression (31.1% Versus. 13.7%, p = 0.012). PD-L1 high-expression also contributed to longer median PFS...GLS-010 demonstrated favorable safety and clinical response in refractory population of lymphoma and solid tumors.
DOI:
https://doi.org/10.1016/j.ejca.2021.01.020
Trial ID:
